When: Price at $350 (deeper flush)

Then: Add 25% tranche

When: MACD histogram positive cross AND close >$368.46 on volume >7M

Then: Add final 25% tranche

HOLD

• 17.8% ROE justifies premium valuation, but current 2.7x P/B is expensive given the stock is +16% above 200 SMA and less than $2 from 52-week high after running 30% from March lows
• MACD histogram flipping from positive to negative and RSI failing to confirm new highs represent early mechanical warning signals at a turning point, not 'rounding errors'
• Q2 earnings showed 47% YoY EPS growth but $4.4 billion came from special items; adjusted 15% growth is solid but represents peak reported numbers already in the price
• Recommended stop at $330 (about 9% below current) sits below the 50 SMA and July consolidation zone, providing structural protection without being triggered by normal 2% intraday volatility; a tighter 1.5x ATR stop at $353 would cause whipsaw losses
• Adding capital at $362 when technicals are flashing caution exemplifies the disposition effect in reverse—chasing performance rather than harvesting it
• Macro tail risks include consumer credit deterioration if unemployment ticks up, commercial real estate pressure, and geopolitical oil shocks that could force Fed action, creating asymmetric downside if soft-landing thesis breaks

→ vs aggressive: MACD reading of negative 0.02 is not a 'rounding error'—the histogram flipping from positive to negative is the first mechanical signal that buying pressure is exhausting at current prices, a warning that should be heeded rather than dismissed

→ vs aggressive: Framing the $354.62 pullback target as a trap that won't materialize is momentum-chasing logic—the bullish scenario assumes trend continuity while ignoring the bearish technical resolution where the stock could flush through the 20 SMA to $340 or $320

→ vs aggressive: The 1.5x ATR stop at $353 is 'egregious' only if you accept tight stops that get triggered by routine 2% intraday whipsaws; a structural stop at $330 gives the trade room to breathe through normal volatility while defining where the thesis actually breaks

→ vs aggressive: Calling $330 a wide stop misframes the issue—the real cost is being stopped out on every market hiccup while the aggressive framework guarantees underperformance over a full cycle

→ vs aggressive: 85% probability of no Fed cuts doesn't eliminate tail risk—higher-for-longer creates nonlinear credit deterioration risk, and 8% recession probability is not symmetric; if soft-landing breaks, JPM faces credit costs, NIM compression, and multiple compression simultaneously

HOLD core position; scale in 2-3% on pullbacks using tiered plan ($358 first tranche, $354.62 second tranche, $350 third tranche); tighten stop to $345

• Five-week trading range: $356 to $365, with 10 EMA at $359.63 and JPM bouncing for nine sessions within this range
• Valuation: 17.8% ROE and 2.7x P/B are justified at $340-$360 but become questionable above $370 requiring heroic NII forecast
• Mild technical warnings: MACD line at 7.16 (above zero), RSI at 65, histogram at minus 0.02 — not sell signals but worth monitoring
• 50 SMA at $338.79 held as support when tested in mid-July; $330 stop is below this tested support level
• Q2 earnings: $4.4B special item is noise; underlying $6.05 adjusted EPS grew 15% YoY with intact NII guidance
• Capital return: $13 billion per quarter; base case supports sequential EPS growth, not collapse
• Macro: 8% recession probability is tail risk, not central case; soft-landing framework intact with Fed on hold
• Suggested tiered scale-in: half at $358 if tested, second tranche at $354.62 (20 SMA), final tranche at $350 on deeper pullback
• ATR-based stops: $356 (1 ATR), $353 (1.5 ATR), $350 (2 ATR) are more honest than $330
• Tightened stop at $345: approximately 5% below current, sits above 50 SMA, provides ~3 ATR of room, would survive July consolidation
• Risk-reward at $358-$359: roughly 2-to-1 upside to upper band versus downside to 50 SMA

→ vs aggressive: The 'you'll never get $354' argument conflates 'strong uptrends don't gift clean pullbacks' with 'chase at $362.' Those are different decisions — data shows scaling in inside the $356-$360 range is more defensible than buying at the upper third where the Bollinger upper band is rejecting price.

→ vs aggressive: The 17.8% ROE and 2.7x P/B don't make any price a bargain in isolation. With momentum plateauing, JPM at the top of a five-month range, and three weeks until the mid-September FOMC, valuation must be evaluated relative to the current macro and technical backdrop — not just in a vacuum.

→ vs conservative: MACD histogram flip (minus 0.02) and RSI divergence (65, not 75) are not screaming sell signals — they are mild warnings. Acting on every mild divergence means never holding a winning position through normal mid-trend consolidations.

→ vs conservative: The $330 stop is 'fearfully anchored' not 'structurally anchored.' JPM kissed the 50 SMA at $338.79 in mid-July and bounced — $330 sits below a historically tested support level. A $330 stop prices in a scenario JPM returns to pre-March levels, which requires an 8% recession tail risk to materialize. A real stop should have a reasonable probability of being hit on adverse but not catastrophic action.

→ vs conservative: The $4.4B Q2 special item is a noise term the market already discounted. The underlying $6.05 adjusted EPS growing 15% YoY does not constitute a 'peak.' The base case is sequential growth as Q3/Q4 prints only need to clear the $6.05 baseline, not match the $7.70 reported figure.